Group 1 - Novo Nordisk's drug Ozempic is expected to see a price cut following negotiations with the Trump administration [1] - Ozempic and Wegovy, both containing semaglutide, have seen increased demand, particularly for weight loss [2][3] - Novo Nordisk is engaged in discussions regarding the "most favored nation" executive order aimed at reducing drug prices for Americans [5][6] Group 2 - The Trump administration's focus has been on aligning U.S. drug prices with those in other developed nations [8] - A recent deal with Pfizer will result in significant price reductions for its medications, with discounts ranging from 50% to 100% [11]